Posted in | News

Caverion Signs Agreement with Novo Nordisk to Deliver New Insulin Production Facility in Denmark

Caverion delivers a Large Project for Novo Nordisk’s new insulin production facility in Hillerød, Denmark

Caverion has signed an agreement with global healthcare company, Novo Nordisk A/S on the delivery of a Large Project for a new pharmaceutical filling factory in Hillerød, Denmark. Caverion is responsible for Project Execution within the discipline of Ventilation. The contract has a volume of approximately EUR 5.4 million.

The facility will produce medicines for the treatment of diabetes and obesity.

“We are very excited to be part of a major new facility. In addition, our role is crucial for ensuring the production capacity of a life-saving medicine. Our previous experience in the pharmaceutical industry is important as this project is demanding and we need to meet very high standards,” says Knut Gaaserud, Executive Vice President & CEO division Denmark-Norway of Caverion.

The factory constitutes an area of 35,000 m2. The facility is expected to be operational in 2019 and it will create 450 new production and engineering jobs in Hillerød where Novo Nordisk already employs 1,900 people.

The project started in June 2016 and ends in February 2017. The builder is Novo Nordisk A/S. The project belongs to Caverion’s real estate users client segment.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.